Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

被引：0

作者：

Michael A Postow

Diana M Cardona

Janis M Taube

Robert A Anders

Clive R Taylor

Jedd D Wolchok

Margaret K Callahan

Michael A Curran

Alexander M Lesokhin

Joseph F Grosso

Christine E Horak

John Cogswell

Jason S Simon

Ashok K Gupta

Mario Sznol

机构：

[1] Memorial Sloan-Kettering Cancer Center,Keck School of Medicine

[2] Duke University School of Medicine,undefined

[3] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined

[4] University of Southern California,undefined

[5] Bristol-Myers Squibb,undefined

[6] Yale University School of Medicine and Yale Cancer Center,undefined

来源：

Journal of Translational Medicine | / 12卷 / Suppl 1期

关键词：

Ipilimumab; Tumor Infiltrate Lymphocyte; Advanced Melanoma; Myeloid Derive Suppressor Cell; Absolute Lymphocyte Count;

D O I：

10.1186/1479-5876-12-S1-O8

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Antonia, Scott J.
Rizvi, Naiyer A.
Chow, Laura Q.
Borghaei, Hossein
Brahmer, Julie R.
Juergens, Rosalyn
Shepherd, Frances A.
Laurie, Scott A.
Gerber, David E.
Goldman, Jonathan
Shen, Yun
Harbison, Christopher
Chen, Allen C.
Gettinger, Scott
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S153 - S153
[42] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
Antonia, Scott Joseph
Brahmer, Julie R.
Gettinger, Scott N.
Chow, Laura Quan Man
Juergens, Rosalyn A.
Shepherd, Frances A.
Laurie, Scott Andrew
Gerber, David E.
Goldman, Jonathan Wade
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Borghaei, Hossein
Rizvi, Naiyer A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[43] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
Rizvi, N. A.
Shepherd, F. A.
Antonia, S. J.
Brahmer, J. R.
Chow, L. Q.
Goldman, J.
Juergens, R.
Borghaei, H.
Ready, N. E.
Gerber, D. E.
Shen, Y.
Harbison, C.
Chen, A. C.
Gettinger, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
[44] CLINICAL ACTIVITY, SAFETY AND SUBPOPULATION RESPONSE ANALYSIS OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS (PT) WITH NON-SMALL CELL LUNG CANCER (NSCLC)
Brahmer, J. R.
Horn, L.
Antonia, S. J.
Spigel, D. R.
Sequist, L. V.
Ahlers, C. M.
Sankar, V.
Kollia, G.
Gettinger, S.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S39 - S39
[45] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
Robert, Caroline
Ascierto, Paolo Antonio
Maio, Michele
Hernberg, Micaela
Schmidt, Henrik
Waxman, Ian
Garbe, Claus
Lebbe, Celeste
Hauschild, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[46] A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies
Lesokhin, Alexander M.
Gutierrez, Martin
Halwani, Ahmad Sami
Ansell, Stephen Maxted
Armand, Philippe
Borrello, Ivan
Segota, Zdenka E.
Cohen, Adam D.
Talpaz, Moshe
Cattry, Deepika
Turner, Tracy
Mezes, Maria
Hartman, Christina
Gupta, Ashok Kumar
Kim, Su Young
Wigginton, Jon M.
Timmerman, John
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[47] Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors
Chow, Laura Quan Man
Gordon, Michael S.
Logan, Theodore F.
Antonia, Scott J.
Bhatia, Shailender
Thompson, John A.
Brahmer, Julie R.
Solberg, Gretchen
Bittner, Rachel
Fontana, David
Grosso, Joseph
Cohen, Lewis J.
Ahlers, Christoph Matthias
Wigginton, Jon M.
Drake, Charles G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[48] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
Motzer, Robert John
Bono, Petri
Hudes, Gary R.
Tomita, Yoshihiko
Ravaud, Alain
Waxman, Ian
Gore, Martin Eric
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[49] Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
Gettinger, S. N.
Horn, L.
Gandhi, L.
Spigel, D. R.
Antonia, S. J.
Rizvi, N. A.
Powderly, J. D.
Heist, R. S.
Carvajal, R. D.
Jackman, D. M.
Sequist, L. V.
Smith, D. C.
Leming, P. D.
Topalian, S. L.
Hodi, F.
Sznol, M.
Harbison, C. T.
Kollia, G. D.
Brahmer, J. R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S34
[50] A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
Chmielowski, Bartosz
Hamid, Omid
Minor, David R.
D'Angelo, Sandra P.
Pennock, Gregory K.
Grossmann, Kenneth
Ascierto, Paolo Antonio
Daud, Adil
Dummer, Reinhard
Hodi, F. Stephen
Lebbe, Celeste
Robert, Caroline
Sosman, Jeffrey Alan
Yang, Arvin
Lambert, Alexandre
Weber, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →